Disease Registry Software Market Report 2025

The disease registry software market size has grown rapidly in recent years. It will grow from $1.39 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be linked to the increasing burden of chronic diseases, expansion of clinical research and trials, rising prevalence of rare diseases, rapid adoption of electronic health records (EHRs), and the widespread occurrence of chronic conditions.

The disease registry software market size is expected to see rapid growth in the next few years. It will grow to $2.38 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be linked to the expanding adoption of value-based care models, increased use of real-world evidence (RWE), growth of precision medicine initiatives, rising incidence of chronic and lifestyle-related diseases, and stronger emphasis on patient-centered healthcare. Key trends during the forecast period include advancements in healthcare IT infrastructure, integration with telehealth and remote monitoring, connection with internet of things (IoT) devices and wearables, enhanced data visualization and dashboards, and use of blockchain for data security and interoperability.

The growing adoption of personalized medicine is expected to drive the expansion of the disease registry software market. Personalized medicine is an approach that customizes treatment and prevention based on an individual's genetic makeup, lifestyle, and environment. This shift is largely driven by advancements in genomics, which allow for the precise identification of genetic variations and the development of tailored treatments. Disease registry software plays a crucial role in personalized medicine by systematically gathering and managing patient health data, enabling the creation of personalized treatment plans and supporting improved clinical decision-making. These systems streamline access to and analysis of data, ultimately enhancing patient outcomes and advancing the field of precision healthcare. For instance, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a substantial increase from 2022. As a result, the growing adoption of personalized medicine is fueling the demand for disease registry software.

Leading companies in the disease registry software market are focusing on creating patient-centric registries, such as digital systems designed to track outcomes and support personalized care. Digital registries are electronic platforms that systematically collect, store, and manage patient health information, replacing traditional paper-based methods. For example, in August 2025, the American College of Cardiology launched the CONNECT-HCM Registry, a nationwide digital registry aimed at improving the understanding and management of hypertrophic cardiomyopathy (HCM), the most common genetic cardiovascular condition. This registry allows for direct patient enrollment across multiple centers, addressing gaps in diagnosis and care. It links registry data with electronic health records via Arboretum’s Hugo Connect platform, enabling researchers to track symptoms, imaging results, treatments, and outcomes over time.

In November 2023, Health Catalyst Inc., a U.S.-based healthcare analytics company, acquired Electronic Registry Systems Inc. (ERS) to enhance its oncology registry capabilities. With this acquisition, Health Catalyst integrates ERS’s cancer data management expertise into its suite of tech-enabled managed services, improving data abstraction, reporting, and analytics for healthcare organizations. ERS is a U.S.-based company specializing in cancer registry software and services.

Major players in the disease registry software market are Optum Inc., IQVIA Holdings Inc., Syneos Health Inc., Epic Systems Corporation, Premier Inc., MRO Corp., ImageTrend Inc., Anju Software Inc., BayaTree Inc., Medrio Inc., ArborMetrix Inc., Cedaron Medical Inc., Evado Pty. Ltd., OpenClinica LLC, Dacima Software Inc., Global Vision Technologies Inc., Ordinal Data Inc., Healthmonix LLC, Axis Clinical Software Inc., and Vanderbilt University.

North America was the largest region in the disease registry software market in 2024. The regions covered in disease registry software report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the disease registry software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Disease registry software is a dedicated digital platform designed to gather, organize, and manage patient information related to specific diseases or medical conditions. It enables healthcare providers, researchers, and policymakers to track disease trends, evaluate treatment outcomes, maintain regulatory compliance, and support clinical decisions to enhance patient care and overall population health.

The primary categories of disease registry software are standalone and integrated. Standalone systems operate independently to collect, manage, and analyze disease-specific patient data without relying on hospital or clinic infrastructure. These databases can be public or commercial, with deployment options including on-premises and cloud-based models, and they serve hospitals, government agencies, research institutions, pharmaceutical companies, and other users.

The disease registry software market research report is one of a series of new reports that provides disease registry software market statistics, including the disease registry software industry global market size, regional shares, competitors with the disease registry software market share, detailed disease registry software market segments, market trends, and opportunities, and any further data you may need to thrive in the disease registry software industry. This disease registry software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The disease registry software market includes revenues earned by entities through patient data management, real-time data collection, integration with electronic health records, analytics and reporting, clinical research support, chronic disease management, and public health surveillance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.